Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02091960
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Completed
Phase Phase 2
Start date August 28, 2014
Completion date January 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04653740 - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer N/A
Recruiting NCT05156619 - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Recruiting NCT05173103 - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT00754325 - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Phase 2
Recruiting NCT04953377 - PFMT Educational Intervention for Patients With Advancer Breast Cancer N/A
Completed NCT03240224 - Bioinformation Therapy for Breast Cancer Phase 2/Phase 3
Recruiting NCT06193525 - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test Phase 2
Completed NCT03312738 - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor Phase 2
Recruiting NCT05063786 - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) Phase 3
Completed NCT03205761 - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer Phase 2
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Active, not recruiting NCT02499146 - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT04456855 - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed NCT04408118 - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Withdrawn NCT04316169 - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Phase 1
Completed NCT00546104 - Phase II Dasatinib Study in Advanced Breast Cancer Phase 2
Completed NCT00387907 - Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer Phase 2